Citation Report
List of articles citing

Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis

DOI: 10.1002/acr.22895
Arthritis Care and Research, 2016, 68, 1751-1757.

Source: https://exaly.com/paper-pdf/65031788/citation-report.pdf
Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Cost-effectiveness Analysis of Treatment Sequence Initiating With Etanercept Compared With Leflunomide in Rheumatoid Arthritis: Impact of Reduced Etanercept Cost With Patent Expiration in South Korea. *Clinical Therapeutics*, **2016**, 38, 2430-2446.e3	3.5	8
21	Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept. *Arthritis Care and Research*, **2017**, 69, 1467-1472	4.7	20
20	Turkish League Against Rheumatism (TLAR) Recommendations for the Pharmacological Management of Rheumatoid Arthritis: 2018 Update Under Guidance of Current Recommendations. *Archives of Rheumatology*, **2018**, 33, 251-271	0.9	1
19	Early Diagnosis and Treatment of Rheumatoid Arthritis. *Primary Care - Clinics in Office Practice*, **2018**, 45, 237-255	2.2	88
18	Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. *Expert Review of Pharmacoeconomics and Outcomes Research*, **2019**, 19, 537-549	2.2	10
17	Illuminating an Invisible Epidemic: A Systemic Review of the Clinical and Economic Benefits of Early Diagnosis and Treatment in Inflammatory Disease and Related Syndromes. *Journal of Clinical Medicine*, **2019**, 8,	5.1	4
16	Cardiovascular Disease Risk in Older Adults and Elderly Patients with Rheumatoid Arthritis: What Role Can Disease-Modifying Antirheumatic Drugs Play in Cardiovascular Risk Reduction?. *Drugs and Aging*, **2019**, 36, 493-510	4.7	6
15	A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients. *Medicine (United States)*, **2019**, 98, e17750	1.8	2
14	Low Persistence Rates in Patients With Rheumatoid Arthritis Treated With Triple Therapy and Adverse Drug Events Associated With Sulfasalazine. *Arthritis Care and Research*, **2019**, 71, 1326-1335	4.7	15
13	Cost-Effectiveness of Combination Disease-Modifying Antirheumatic Drugs Versus Tumor Necrosis Factor Inhibitors in Active Rheumatoid Arthritis: A Pragmatic, Randomized, Multicenter Trial. *Arthritis Care and Research*, **2020**, 72, 334-342	4.7	3
12	Hydrolysable tannin-rich fraction from Terminalia chebula Retz. fruits ameliorates collagen-induced arthritis in BALB/c mice. *Inflammopharmacology*, **2020**, 28, 275-287	5.1	4
11	Quantitative Predictive Modelling Approaches to Understanding Rheumatoid Arthritis: A Brief Review. *Cells*, **2019**, 9,	7.9	8
10	Real-World Outcomes Associated With Methotrexate, Sulfasalazine, and Hydroxychloroquine Triple Therapy Versus Tumor Necrosis Factor Inhibitor/Methotrexate Combination Therapy in Patients With Rheumatoid Arthritis. *Arthritis Care and Research*, **2021**, 73, 1114-1124	4.7	2
9	Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment. *Current Rheumatology Reports*, **2020**, 22, 44	4.9	6
8	Systematic Literature Review of Economic Evaluations of Biological Treatment Sequences for Patients with Moderate to Severe Rheumatoid Arthritis Previously Treated with Disease-Modifying Anti-rheumatic Drugs. *Pharmacoeconomics*, **2020**, 38, 459-471	4.4	7
7	Cost-utility analyses of targeted immunomodulators in rheumatoid arthritis: systematic review. *Journal of Medical Economics*, **2020**, 23, 610-623	2.4	
6	Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients. *Medicine (United States)*, **2020**, 99, e16635	1.8	3

5	Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. *SN Comprehensive Clinical Medicine*, **2021**, 3, 838-854	2.7	0
4	Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World. *Journal of Inflammation Research*, **2020**, 13, 1141-1150	4.8	1
3	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. *Health Technology Assessment*, **2017**, 21, 1-258	4.4	27
2	Cost-utility of COBRA-light versus COBRA therapy in patients with early rheumatoid arthritis: the COBRA-light trial. *RMD Open*, **2017**, 3, e000502	5.9	3
1	Hydroxychloroquine: Chemistry and Medicinal Applications. **2023**, 106,		0